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also positive for desmin and h-caldesmon, suggesting that a fraction 
of these cells have a smooth muscle-like phenotype. In mixed adeno-
carcinoma with a BAC component, subepithelial myoﬁbroblasts were 
present in the BAC componenet, but there seemed to be a gradual loss 
of a typical subepithelial pattern of myoﬁbroblasts in invasive areas; 
they either disappeared partially or formed concentric layers of myo-
ﬁbroblasts around cancer cell nests. In most cases of frankly invasive 
adenocarcinoma, subepithelial myoﬁbroblasts were absent and bundles 
of myoﬁbroblasts emerged in cancer stroma. To further characterize the 
relationship to stromal invasion, we immmunostained adjacent sections 
for laminin-1 and collagen type 4 to highlight basement membranes, 
and then compared the results with smooth muscle α-actin staining. As 
expected, stromal invasion was associated with disruption of basement 
membranes and loss of a typical subepithelial pattern of myoﬁbroblasts. 
Interestingly, however, a subset of invasive adenocarcinomas partially 
retained subepithelial myoﬁbroblast, and survival analysis showed that 
invasive tumors with partial retention of subepithelial myoﬁbroblasts 
were associated with low rates of lymphatic and vascular invasion, 
lymph node involvement, and better patient survival. 
Conclusions: The results of this study suggest that subepithelial 
myoﬁbroblasts occur in bronchiolo-alveolar carcinomas, but they were 
gradually replaced by typical stromal myoﬁbroblasts during progres-
sion into invasive cancer. A subset of invasive adenocarcinomas retains 
subepithelial myoﬁbroblasts. Analysis of subepithelial myoﬁbroblasts 
may be helpful in deﬁning a subset of lung adenocarcinoma with good 
prognosis. 
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Background: Several researchers have reported the efﬁcacy of ad-
juvant chemotherapy in resected stage IB non-small cell lung cancer 
(NSCLC) patients. Due to the considerable variation in histological 
ﬁndings and outcomes of stage IB lung adenocarcinoma, it appeared 
there were unidentiﬁed subgroup factors. These factors affect treatment 
recommendations and choices. Identifying patients who do not need 
adjuvant chemotherapy saves patient stress and medical resources. This 
study’s aim was to investigate resected stage IB adenocarcinoma pa-
tient prognostic factors and identify a subgroup with a better outcome, 
where adjuvant chemotherapy might not be beneﬁcial and needed.
Methods: We reviewed records of 413 consecutive stage I lung 
adenocarcinoma patients who underwent complete surgical resection 
and systematic lymph node dissection at the National Cancer Center 
Hospital East from July 1992 through March 2000, to ﬁnd 106 stage IB 
patients for prognostic factor investigation. We evaluated four clinical 
factors: gender, age (<70 vs. ≥70 years), smoking history (positive vs. 
negative), and serum carcinoembryonic antigen (CEA) level (<5 vs. ≥5 
ng/ml). Seven pathological factors were also evaluated: maximum tu-
mor diameter (<5 vs. ≥5 cm), differentiation grade (well vs. moderately 
or poorly differentiated), lymphatic permeation (positive vs. negative), 
vascular invasion (positive vs. negative), pleural invasion (positive 
vs. negative), and bronchioloalveolar carcinoma (BAC) component 
dominance (positive vs. negative). BAC component dominance was 
considered positive if the histological evaluation found half or more of 
the tumor consisted of a BAC component. A subgroup with better out-
comes was identiﬁed and their survival compared with that of all stage 
IA patients who underwent surgical resection during the same period.
Results: The 5-year survival rate of all the stage IB lung adenocar-
cinoma patients was 81.7%. Univariate analyses found lymphatic 
permeation (p<0.001), vascular invasion (p=0.003), pleural invasion 
(p=0.001) and BAC-dominant histology (p=0.003) were signiﬁcant 
unfavorable prognostic factors. A multivariate analysis demonstrated 
positive pleural invasion (p=0.02) was an independent unfavorable 
prognostic factor. The stage IB lung adenocarcinoma patients 5-year 
survival rate with and without pleural invasion of 63% and 89%, 
respectively shows the invasion factor impact. Additionally, stage IB 
adenocarcinoma patients without pleural invasion overall survival rate 
was very similar to that of stage IA patients (92.7%; p=0.78). 
Conclusions: Pleural invasion is a factor that should be considered 
before recommending adjuvant chemotherapy to stage IB lung adeno-
carcinoma patients. The outcome for stage IB lung adenocarcinoma 
patients without pleural invasion is almost identical to stage IA patients 
where adjuvant chemotherapy has not shown an advantage. Adjuvant 
chemotherapy probably is not necessary or beneﬁcial for stage IB 
patients without pleural invasion.
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The presence of epidermal growth factor receptor (EGFR) tyrosine 
kinase (TK) mutations signiﬁcantly correlates with tumor sensitivity to 
tyrosine kinase inhibitor. Importantly, this mutation underlies respon-
siveness of the most predominant histologic subtype, adenocarcinoma. 
To clarify the correlation with EGFR mutations and pathological 
ﬁndings of adenocarcinomas of Japanese patients, detailed patho-
logical features of the tumor were examined. Total of 107 surgically 
resected adenocarcinomas were investigated. Seventeen cases treated 
with geﬁtinib for relapse were included. We reviewed medical records, 
pathology slides and examined EGFR mutations in exon 18-21. EGFR 
mutations were found in sixty ﬁve (60.7%) patients and detected in 
all four exons. EGFR mutations were signiﬁcantly associated with 
female gender (P<0.01), non-smoker status (P<0.05), hobnail cell type 
dominancy (P<0.0001), and papillary subtype (<0.0001). In addition, 
detailed pathological examination represented that the existence of 
bronchioloalveolar carcinoma (BAC) and micropapillary pattern (MPP) 
component was signiﬁcantly associated with EGFR mutations (P<0.05 
and <0.05, respectively). In seventeen patients with geﬁtinib treatment, 
